EDSA
Edesa Biotech, Inc.
There isn't enough reported data to score EDSA yet.
EDSA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
EDSA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
EDSA PE Valuation
EDSA has no meaningful PE right now: it lost money over the past year.
EDSA Forward outlook
There aren't enough analyst estimates for EDSA to show an outlook.
EDSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.61 | -$0.28 |
| Q1 2026 | -$1.26 | +$0.34 |
| Q4 2025 | -$1.07 | +$0.81 |
| Q3 2025 | -$1.27 | +$0.66 |
| Q2 2022 | -$9.03 | -$1.82 |
| Q1 2022 | -$8.93 | -$2.84 |
| Q4 2021 | -$8.19 | -$2.24 |
| Q3 2021 | -$7.70 | -$2.52 |
EDSA is still losing money, but far less than before: $1.61 per share over the past year, against $26.92 at its worst in late 2019.
EDSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2020 | $500 | -100% |
EDSA's revenue has slid since its 2019 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2020 | -402095% | -401858 points |
| Q2 2020 | -1608% | N/A |
| Q1 2020 | -1372% | N/A |
| Q4 2019 | -1026% | N/A |
| Q3 2019 | -237% | N/A |
EDSA's operating margin was −402095% last quarter, down 401858 points from the same quarter a year ago, near the bottom of its range since 2019.
EDSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.1M | -$1.4M |
| Q1 2026 | -$2M | +$366.7K |
| Q4 2025 | -$2.1M | -$570.1K |
| Q3 2025 | -$1.7M | -$754K |
| Q2 2025 | -$1.7M | -$844.3K |
| Q1 2025 | -$2.4M | -$723.1K |
| Q4 2024 | -$1.5M | -$110.7K |
| Q3 2024 | -$967K | +$501K |
EDSA has burned cash in almost every quarter: −$9M over the past year, against −$7M the year before.
EDSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.5% | +466K shares |
| 1 year | +70% | +3.7M shares |
| 3 years | +206% | +6.1M shares |
| 5 years | +442% | +7.3M shares |
| Available history | +735% | +7.9M shares |
EDSA has 9M diluted shares, up 70% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2019 | — |
EDSA Net Leverage
EDSA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EDSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 3.4 | Oversold |
EDSA's weekly RSI is 35 (neutral) and its Stochastic is 3 (oversold).
EDSA PE vs Healthcare Sector
EDSA has no meaningful PE right now: it lost money over the past year.
EDSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.94 | 29% below |
| 20 week MA | $4.39 | 53% below |
| 50 week MA | $4.97 | 58% below |
| 100 week MA | $3.57 | 42% below |
| 200 week MA | $4.39 | 53% below |
EDSA is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
EDSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.4 | $33.5 | +18% |
| 2021 | $33.5 | $45.3 | +35% |
| 2022 | $45.3 | $14.8 | -67% |
| 2023 | $14.8 | $4.57 | -69% |
| 2024 | $4.57 | $1.85 | -60% |
| 2025 | $1.85 | $1.44 | -22% |
| 2026 YTD | $1.44 | $2.08 | +44% |
EDSA has finished four years in a row lower, and it's up 44% so far in 2026.